Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.49 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040729 | 0.94 | FDFT1 (0.53) | RAB9AALDH1A1NPC1SMN1; SMN2FDFT1 | |
| SCHEMBL15952966 | 0.88 | CA12 (0.50) | RAB9AALDH1A1NPC1LMNAHPGD | |
| SCHEMBL3033970 | 0.85 | FDFT1 (0.55) | RAB9AALDH1A1NPC1LMNAHPGD | |
| SCHEMBL21138877 | 0.81 | ALDH1A1 (0.57) | RAB9AALDH1A1NPC1LMNAHPGD | |
| SCHEMBL31386208 | 0.81 | ALDH1A1 (0.42) | RAB9AALDH1A1NPC1HPGDSMN1; SMN2 | |
| SCHEMBL9509660 | 0.81 | PROKR1 (0.60) | RAB9AALDH1A1NPC1LMNAHPGD | |
| SCHEMBL1789154 | 0.81 | ALDH1A1 (0.63) | RAB9AALDH1A1NPC1LMNASMN1; SMN2 | |
| SCHEMBL31386285 | 0.79 | PDE4B (0.53) | ALDH1A1LMNASMN1; SMN2FDFT1CYP19A1 | |
| SCHEMBL4003420 | 0.79 | CA12 (0.59) | RAB9AALDH1A1NPC1LMNAHPGD | |
| SCHEMBL28904415 | 0.78 | BTK (0.49) | RAB9AALDH1A1NPC1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2401265-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099054-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | RAB9A 989/4885ALDH1A1 1356/4885NPC1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.